Statements of the M alaysian S ociety of G astroenterology & H epatology and the N ational H eart A ssociation of M alaysia task force 2012 working party on the use of antiplatelet therapy and proton pump inhibitors in the prevention of gastrointestinal bleeding

The working party statements aim to provide evidence and guidelines to practising doctors on the use of antiplatelet therapy and proton pump inhibitors ( PPI s) in patients with cardiovascular risk as well as those at risk of gastrointestinal ( GI) bleeding. Balancing the GI and cardiovascular risk and benefits of antiplatelet therapy and PPI s may sometimes pose a significant challenge to doctors. Concomitant use of anti‐secretory medications has been shown to reduce the risk of GI bleeding but concerns have been raised on the potential interaction of PPI s and clopidogrel. Many new data have emerged on this topic but some can be confusing and at times controversial. These statements examined the supporting evidence in four main areas: rationale for antiplatelet therapy, risk factors of GI bleeding, PPI –clopidogrel interactions and timing for recommencing antiplatelet therapy after GI bleeding, and made appropriate recommendations.